Medicamen Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
February 10, 2023 at 03:41 pm IST
Share
Medicamen Biotech Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 355.82 million compared to INR 326.41 million a year ago. Revenue was INR 362.11 million compared to INR 334.68 million a year ago. Net income was INR 37.65 million compared to INR 37.79 million a year ago. Basic earnings per share from continuing operations was INR 2.98 compared to INR 3.09 a year ago. Diluted earnings per share from continuing operations was INR 2.98 compared to INR 3.09 a year ago.
For the nine months, sales was INR 1,022.02 million compared to INR 926.91 million a year ago. Revenue was INR 1,043.18 million compared to INR 940.74 million a year ago. Net income was INR 109.54 million compared to INR 121.52 million a year ago. Basic earnings per share from continuing operations was INR 8.66 compared to INR 9.95 a year ago. Diluted earnings per share from continuing operations was INR 8.66 compared to INR 9.95 a year ago.
Medicamen Biotech Limited is an India-based integrated pharmaceutical and life sciences solution provider company. The Company is engaged in manufacturing of diverse range of pharmaceutical products oral solids, oral liquids, ointment for non-oncology products range and also produces tablets, capsule/lyohilized/dry powder injections for oncology product range. It focuses on oncology therapeutics, and other generics. The Company manufactures a range of products, including tablets, capsules, liquid syrup, dry syrup, such as beta-lactum and non-beta lactum, and ointments. The Company primarily focuses on oncology therapeutics. It is also focused on other therapeutic areas, such as cardiology, central nervous system (CNS), diabetology and pain management. Its oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, Bortezomib, Busulfan, Capecitabine, Cisplatin, Erlotinib HCL, Gefitinib, Imatinib mesylate, Lenalidomide, Letrozole, Melphalan, and Pazopanib.
MEDICAMEN BIOTECH LIMITED 